Physician profile
Kenneth E Saland
NPI 1336148550
$3,489.12
in general payments reported to CMS, 2019-2025
32 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $272 · 2021: $476 · 2022: $763 · 2023: $447 · 2024: $575 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $563.57 | 2019-2025 | |
| Boston Scientific Corporation | $405.48 | 2019-2024 | Watchman Flx |
| Pfizer INC. | $380.70 | 2019-2025 | |
| Heartflow, INC. | $361.54 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $238.56 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $143.57 | 2019-2023 | Xarelto |
| Abiomed | $132.55 | 2021 | |
| Amgen INC. | $123.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.04 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $113.27 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $112.18 | 2022-2023 | Lutonix Drug Coated Balloon |
| Cordis US Corp. | $111.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.65 | 2019-2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $88.02 | 2022-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $70.47 | 2019-2025 | Jot Dx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 200 LLC | $51.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $45.18 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $43.22 | 2024 | |
| Scpharmaceuticals INC. | $36.06 | 2024 | |
| Astellas Pharma US INC | $34.02 | 2019-2020 | |
| Itamar Medical INC | $30.44 | 2022 | |
| Resmed Corp | $22.67 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $21.04 | 2025 | Opsumit |
| Siemens Medical Solutions USA, INC. | $20.41 | 2019 | |
| Cvrx, INC. | $18.13 | 2025 | Barostim Neo System |
| Chiesi USA, INC. | $17.82 | 2025 | Cleviprex, Kengreal |
| Esperion Therapeutics, INC. | $17.59 | 2020 | |
| Teleflex LLC | $16.95 | 2022 | |
| Angiodynamics, INC. | $15.81 | 2019 | |
| Merck Sharp & Dohme LLC | $15.35 | 2022 | |
| Tactile Systems Technology INC | $12.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Saland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.